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Abstract
The Hepatitis C virus (HCV) infection exhibits a high global prevalence frequently associ-
ated with hepatocellular carcinoma, taking years to develop. Despite the standardization of
highly sensitive HCV quantitative RT-PCR (qRT-PCR) detection methods, false-negative
diagnoses may be generated with current methods, mainly due to the presence of PCR
inhibitors and/or low viral loads in the patient’s sample. These false-negative diagnoses
impact both public health systems, in developing countries, and an in lesser extent, in devel-
oped countries, including both the risk of virus transmission during organ transplantation
and/or blood transfusion and the quality of the antiviral treatment monitoring. To adopt an
appropriate therapeutic strategy to improve the patient’s prognosis, it is urgent to increase
the HCV detection sensitivity. Based upon previous studies on HBV, we worked on the
capacity of the scavenger acute phase protein, Apolipoprotein H (ApoH) to interact with
HCV. Using different approaches, including immunoassays, antibody-inhibition, oxidation,
ultracentrifugation, electron microscopy and RT-PCR analyses, we demonstrated specific
interactions between HCV particles and ApoH. Moreover, when using a two-step HCV
detection process, including capture of HCV by ApoH-coated nanomagnetic beads and a
home-made real-time HCV-RT-PCR, we confirmed the presence of HCV for all samples
from a clinical collection of HCV-seropositive patients exhibiting an RT-PCRCOBAS1 Taq-
Man1 HCV Test, v2.0 (COBAS)-positive result. In contrast, for HCV-seropositive patients
with either low HCV-load as determined with COBAS or exhibiting HCV-negative COBAS
results, the addition of the two-step ApoH-HCV-capture and HCV-detection process was
able to increase the sensitivity of HCV detection or more interestingly, detect in a genotype
sequence-independent manner, a high-proportion (44%) of HCV/RNA-positive among the
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Introduction
Until the recent introduction of hepatitis C virus (HCV) screening tests, this viral infection has
represented the major cause of blood transfusion-associated hepatitis [1]. Near 170 million
people worldwide are infected with HCV [2], a prevalence about four-fold higher than that of
HIV. More than 70% of the HCV-infected individuals develop a chronic infection considered
as a major cause of liver cirrhosis and hepatocellular carcinoma [3]. Other lympho-proliferative
disorders may also be associated with HCV infection, including mixed cryoglobulinemia (MC)
and Non-Hodgkin’s lymphoma (NHL) [4]. Although the HCV pathogenesis is not well under-
stood, viral infection progresses slowly and often ends in chronic diseases. HCV mainly targets
the liver cells [5], but this virus may also replicate in extra-hepatic cells such as T, B and mono-
cyte cell subsets from chronically infected individuals [6].
HCV is a small enveloped, positive strand RNA virus belonging to the Hepacivirus genus
from the Flaviviridae family [7]. Based upon the sequence heterogeneity of its genome, HCV is
classified into six major genotypes and more than 100 subtypes [8]. Its genome of approxi-
mately 9 600 nucleotides encodes a polyprotein precursor of about 3 000 amino acids. This
viral polyprotein is cleaved by both viral and host proteases to generate mature structural pro-
teins, including the capsid and two glycosylated envelope proteins (E1 and E2), as well as non
structural proteins. Reliable in vitro propagation systems are pending, infectious HCV virions
have not yet been isolated and functionally characterized. Heterogeneous viral populations
from human sera have been reported, including defective particles [9], such as non-enveloped
nucleocapsids [10, 11] as well as virions bound to either immunoglobulins or serum β lipopro-
teins [12–14].
Although the whole process of HCV cell entry mechanisms remains unclear, several lines of
evidence show that the HCV envelope interacting with cell surface proteins is involved in the
initiation of infection by mediating virus-host cell membrane interaction [15]. Thus, it has
been reported that cell surface heparan sulphates [16] and proteins including the tetraspanin
CD81 [17], the scavenger receptor class B type 1 [18], the LDL receptor [19] and the asialogly-
coprotein receptor [20] could mediate the E2 binding and subsequent HCV internalization.
However, as most of the studies on HCV cell entry are generated by in vitromodels, it is still
unclear whether any of the prior cited molecules could act as a functional receptor on human
hepatocytes [21].
HCV/RNA-containing particles exhibit highly heterogeneous densities [22, 23]. The parti-
cles corresponding to different fractions yielded after gradient-density centrifugation could be
completely, partially or not at all co-precipitated with an anti-beta lipoprotein serum [12].
Consequently, this observation suggests an association between the virus with plasma lipopro-
teins, including LDL, VLDL [14] and HDL [24–26]. The lipoproteins particles are complex
aggregates of lipids (mainly triglycerides, phospholipids and cholesterol) and proteins (apoli-
poproteins). A recent study [27] has shown that the serum VLDL-TG/non-VLDL-TG ratio,
which focused on TG metabolic alterations, may be an early indicator of HCV-related chronic
hepatitis. Among the apolipoproteins, ApoA-I, ApoB, ApoC-I and ApoE are involved in the
Interactions between HCV and the ApoH Acute Phase Protein
PLOS ONE | DOI:10.1371/journal.pone.0140900 October 26, 2015 2 / 24
additional role in the study design, data collection and
analysis, decision to publish or preparation of the
manuscript. The specific roles of these authors are
articulated in the 'author contributions' section.
Competing Interests: IRD and ApoH-Technologies
(ApoH-T) have filed patent applications on detection
of pathogens, including HCV infection (FR2927172
(B1) “Detecting infectious components in a biological
fluid sample comprises contacting microbeads loaded
with beta 2 glycoprotein I with the sample in the
presence of oxidizing metal ions”. Inventors: STEFAS
ILIAS [FR]; VEAS FRANCISCO [FR]; Applicant:
ApoH:Technologies SA (www.apohtech.com);
Application number: FR20080000553 20080201;
Priority number: FR20080000553 20080201;
Classification: (i) international: C12Q1/04; C12Q1/70;
G01N33/569; G01N33/68; (ii) cooperative: C12Q1/
04; G01N33/56911; G01N33/56983). Marketed
products are on www.apohtech.com. Francisco Veas
and Ilias Stefas respectively, serve as scientific
advisor for ApoH-Tand CEO of the company. In
addition, ST-G and EL-B are part of the ApoH-T staff
and DG was part of ApoH-T. DB is the CEO of
Immunoclin Corp. MK and HE are employed by
GenExpress GmbH. MK and HE are consultants for
ImmunoClin Corporations. There are no further
patents, products in development, or marketed
products to declare. This does not alter the authors'
adherence to all PLOS policies on sharing data and
materials.
infectivity, production and transport of HCV [28–33]. This association has been correlated
with both the virus infectivity and genotype. However, although these lipoproteins and apoli-
poproteins are required for HCV infectivity and production, they are not HCV-specific, since
they interact with other viruses. Thus, ApoA-I interacts with dengue and hepatitis B viruses
[34, 35]. VLDL, HDL and LDL interact with rotavirus, dengue and herpes simplex viruses [36–
38].
Apoliporotein H (ApoH), also known as β2–glycoprotein I (β2–GPI), has been primarily
described as a mitochondrial agglutinin, exhibiting a strong affinity for negatively-charged
phospholipids [39]. A phospholipid-binding site, located in the fifth domain of ApoH has been
identified [40, 41]. It has been clearly demonstrated that HCV from human-infected plasma
co-elutes with VLDL. This association with host’s lipoproteins may explain the low buoyant
density of HCV (<1.10 g/mL). This reported observation was associated with the highest infec-
tious material [42]. Because several lines of evidence suggest that HCV circulates in the blood-
stream as a hybrid lipoviral particle, so called LVP [43], it is possible to hypothesize that ApoH
could bind to HCV particles through anionic phospholipids of the viral envelope. We have pre-
viously reported the association of ApoH with hepatitis B virus (HBV) human immunodefi-
ciency virus (HIV) and rotavirus [44–46]. Altogether, these results led us to investigate
whether the ApoH, a protein partially associated with the plasma lipoprotein fraction [39], has
the capacity to bind to HCV particles. The earliest detection of viruses is a crucial step to estab-
lish an individual accurate diagnosis of the disease, to engage an appropriate therapeutic man-
agement (including drug monitoring efficiency) leading to improved prognostic for the
patient. This crucial step is also necessary in public health to set up the appropriate counter-
measures for both control and/or prevention of the dissemination of the virus, particularly in
developing countries. Despite the development of HCV quantitative RT-PCR and derived
methods to detect and quantify the viral load in patients, HCV occult infections have been
reported [47, 48]. An occult HCV infection is mainly characterized by the presence of HCV/
RNA in liver cells or in peripheral blood mononuclear cells, but with negative detection of
HCV/RNA in serum using current tests, in the absence or the presence of anti-HCV antibod-
ies. A recent Italian cohort study evidenced that HCV occult infections may occur in popula-
tions selected for not having any hepatic disease. These studies concluded that a potential risk
of infectious HCV spreading should be considered [49], in particular during organ transplanta-
tion or blood transfusion, mainly in developing countries with poor diagnostic settings [50]. In
Egypt, regular sexual unprotected intercourses between HCV-positive patients and HCV-nega-
tive spouses results in a prevalence about 4% of HCV occult infections among the previous
HCV-negative individual partners [51]. In addition, recent investigations on organ transplant
have identified an increased risk of HCV transmission by organ donors harbouring very recent
HCV infection with negative nucleic acid testing to naive individuals [52]. These facts point
out the urgent need for innovative methods to further improve the HCV diagnostics and over-
come any risk of residual viral loads.
Since HCV circulates in the bloodstream as an enveloped viral particle and based on the
capacity of ApoH to bind some anionic phospholipids, we hypothesized that ApoH binds
HCV, and that this binding is done through phospholipids from the HCV envelope. This study
mainly demonstrates the capacity of ApoH to bind HCV, which ultimately allowed the capture
and concentration of HCV from human fluids (sera or plasma) thus enhancing the detection
sensitivity of the HCV molecular diagnostics. To this purpose, specific capture tools have been
developed, including ApoH-coated solid supports such as nanomagnetic beads and ELISA
immunoassay on microtitration plates.
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Materials and Methods
Reagents
Bovine serum albumin (BSA) was purchased from Fluka (Buchs, Switzerland), 20% human
albumin solutions were obtained from the Etablissement Français du Sang in Montpellier,
France and α1-acid glycoprotein was purchased from Sigma (St. Louis, Mo, USA). Maxisorp
microtiter plates (96-well) were supplied by NUNC (Roskilde, Denmark). The following
monoclonal and polyclonal antibodies were used: the mouse anti-human ApoH, 8C3, MAb
was kindly donated by J. Arvieux [53]), the mouse anti-human thyroglobulin 2, TG2, MAb was
a kind gift from Sanofi, Montpellier, France, the mouse anti-HCV/E2, 3A2C11, MAb was
kindly provided by BioMérieux, (Lyon, France) and a goat peroxidase-conjugated anti-mouse
serum was purchased from Sigma (St. Louis, Missouri, USA). The DNA molecular size marker
1 Kb Plus DNA Ladder was purchased at Life Technologies (Saint Aubain, France). Nucleic
acids sequencing was carried out by MilleGen (Toulouse, France). ApoH was purified from
human plasmatic albumin solutions as previously described [45].
Serum samples
Serum samples from healthy blood donors and sera from HCV-infected patients with chronic
hepatitis were obtained from the following laboratories: Etablissement Français du Sang of
Montpellier, France; the Virology Laboratories of the Centre Hospitalier Universitaire of Gre-
noble, France. The presence of anti-HCV antibodies and HCV-RNA in hepatitis patient’s sera
were respectively established by using both ELISA (ELISA 3, Ortho Diagnostic Systems, Rari-
tan, NJ, USA) and real-time HCV RT-PCR with a limit of detection comprised between 9.3
and 20 IU/mL (COBAS1 TaqMan1HCV Test, v2.0, Roche Diagnostics, Basel, Switzerland).
HCV capture by ApoH-coated nanomagnetic beads and viral RT-PCR
detection
A total of 10 μL of ApoH-coated nanomagnetic bead suspension (ApoH-Technologies, Mont-
pellier, France) was added to 100 μL of serum diluted in an acetate acidic buffer. The mixture
was incubated at 6°C for 30 min on an Eppendorf Thermomixer Comfort (Lyon, France). The
tube was placed against a magnet for four minutes and the unbound serum fraction was
removed. The beads were then resuspended in 560 μL of lysis buffer (AVL from the QIAamp1
Viral RNAMini Kit, Qiagen, Germany) containing 8 units of RNase OUT (Life Technologies,
Carlsbad, USA) and 5.6 μg RNA carrier and heated to 35°C for 10 min. The supernatant was
separated from the beads by retaining them with a magnet. The viral nucleic acids in the super-
natant were purified according to the procedure described in the QIAamp1 Viral RNAMini
Kit (QIAGEN, Germany).
We created an “open” home-made HCV-reverse transcription and polymerase chain
reaction (RT-PCR) that was carried out by using KY80 primers (sense: 50-GCAGAAAGCGTC
TAGCCATGGCGT-30) and KY78 (antisense: 50-CTCGCAAGCACCCTATCAGGCAGT-30)
leading to the amplification of a sequence of 244 nucleotides within the conserved 50NC region
of the HCV genome [54]. For end-point PCR and in-gel results, the following protocol was
applied. HCV/RNA was incubated with the primers for 7 min at 70°C to linearize the RNA and
cooled on ice. RT was allowed to proceed for 15 min at 50°C and was followed by 15 min incu-
bation at 95°C to inactivate the reverse transcriptase, activate the polymerase and facilitate
denaturation of RNA-DNA heteroduplexes. PCR amplification proceeded with 40 cycles at
94°C for 60 s, 55°C for 30 s and 72°C for 60 s and a final extension step at 68°C for 7 min. The
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RT-PCR mixture was carried out by using QIAGEN1OneStep RT-PCR Kit, in accordance
the manufacturer's procedure (Qiagen, Germany).
For the “open” home-made quantitative HCV RT-PCR (qRT-PCR), the following protocol
was applied. HCV/RNA was incubated with random N6 primers for 6 min at 65°C to linearize
the RNA and cooled on ice. Primer annealing was performed for 10 min at 25°C. RT was
allowed to proceed for 50 min at 37°C and was followed by 15 min incubation at 70°C (accord-
ing to Life Technologies™ procedure M-MLV RT kit). The cDNA obtained was 10-fold diluted
and amplified in a 480 LightCycler with the SybrGreen I master mix including KY78 and KY80
primers (Roche™, Basel, Switzerland). After 5 min denaturation at 95°C, 45 cycles were per-
formed: 10 s at 95°C, 10 s at 60°C, 10 s at 72°C and fluorescence was measured in each cycle
during extension. The DNA was heated to 95°C for 5 min and cooled to 65°C for 1 min before
measuring the fluorescence during a final melting curve from 65°C to 97°C. An HCV plasmid
(pGEM-T easy, Promega, with an HCV/PCR-insert) was used as template to make the stan-
dard curve and compute HCV copies.
Enzyme immunoassay using ApoH for the HCV capture
ApoH-coated microtiter plates (96-well) were saturated with 200 μL of 3% BSA in Tris 50 mM,
pH 9.0, NaCl 0.15 M, for 1 h at 37°C and 4 washes with 10 mM phosphate buffer, pH 7.2, 0.15
M NaCl (PBS) containing 0.005% of Tween 20 (Sigma, St. Louis, Mo, USA). One hundred
microliters of serum or viral preparations from CsCl gradient separation diluted in a Tris
50 mM, pH 7.6 buffer were added per well. After 1 h incubation at 37°C followed by 4 washings
with PBS, 100 μ L of anti-HCV or irrelevant MAb was added and incubated at 37°C for 1 h.
Subsequently, the wells were washed 4 times with PBS and 100 μL of peroxidase-conjugated
polyclonal anti-mouse serum were added. Finally, after 1 h incubation at 37°C, the wells were
washed 6-times with PBS and O-Phenylene-Diamine (OPD, Sigma, St. Louis, Missouri, USA)
was added according to the manufacturer's procedure. Optical density was measured at 492
nm with a Titertek Multiskan Plus spectrophotometer (Flow Laboratories, USA). The data
were expressed as a P/N ratio (mean ratio ± standard deviation, SD) which represents the
mean of four replicate absorbance values of the sample (P) as compared to the mean absor-
bance value of at least 5 negative control sera (N).
Gradient centrifugation of serum
To purify HCV particles from serum, 10 mL of pooled serum samples from either 20 HCV-
infected patients or 20 healthy carriers were used for this study. After filtration through two
layers of gauze, serum was centrifuged without adjustment of density for 1 h at 436,000 x g at
4°C in a TLA-120.2 fixed angle rotor (Beckman, Fullerton, CA). After centrifugation, three
fractions were respectively recovered: the yellow cake (VLDL) phase located over the superna-
tant, the supernatant and the pellet. The VLDL fraction was resuspended in 0.15 M NaCl solu-
tion and the centrifugation was repeated twice and stored for further analyses. The pellet was
suspended in PBS buffer and re-centrifuged twice under the same conditions. The final pellet
was resuspended in a final PBS volume corresponding to a 1/10 of the initial serum volume.
One hundred microliter portions of these HCVp concentrates were layered onto 900 μL of
either a sucrose or a CsCl gradient [10–60% (w/w)] and centrifuged for 18 h at 300,000 x g at
4°C.
Plasma lipoprotein separation
Duplicate samples of freshly-collected EDTA-plasma were used to separate the three major
lipoprotein classes by sequential, isopycnic centrifugation in a TLA-120.2 fixed angle rotor
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(Beckman, Fullerton, CA), as described previously [55]. Density (r) adjustments were made
with stock solutions of KBr in 0.15 M NaCl and four fractions were obtained: very-low density
lipoproteins (VLDL; r<1.006 g/L), low-density lipoproteins (LDL; r: 1.006–1.063 g/L), high-
density lipoproteins (HDL; r: 1.063–1.21 g/L), and very-high-density lipoproteins (r>1.21 g/L,
which also include bulk plasma proteins). Each fraction was collected, extensively dialyzed
against 150 mMNaCl/ 0.24 mM EDTA pH 7.4 at 4°C and filtered through 0.22 μm-pore size
filters (Millipore S.A., St Quentin, France).
Electron microscopy
Samples of HC-VP (Hepatitis C virus particles) isolated from sucrose gradient were incubated
in 2% glutaraldehyde in PBS and applied to an ApoH-coated400-mesh Formvar-carbon-coated
copper grid for approximately 2 min. Excess fluid was drawn away with filter paper. The sam-
ple was then negatively stained with 1% (w/v) filtered aqueous uranyl acetate for 2 min and,
after washing in 1% uranyl acetate, examined using a Zeiss EM 10C/CR transmission electron
microscope, as described previously [44].
Statistical analyses
Bland-Altman plot analysis was performed to assess the agreement level between the quantifi-
cation of HCV/RNA with and without ApoH-sample pretreatment method. ANOVA multi-
parametric tests have been done using the GraphPad PRISM 5 software™.
Ethic statements
An archived collection of sera from HCV-seropositive human patients with or without a viral
load detection determined by a quantitative real-time PCR technology using the COBAS1
TaqMan1HCV Test, v2.0 were used for this study (Metropolitan French USDEP project) and
were part of an already-established collection "HCV-LO-2005-2006" of anonymized leftover
samples at the Virology Lab of The University Hospital Center (CHU) “La Tronche”, Grenoble,
France. The shipping of these clinical samples for research purposes to the Laboratoire d’Im-
muno-Physiopathologie Moléculaire Comparée (Montpellier, France) during 2005 and 2006,
were perfectly in line with the French ethical regulations. Healthy donors samples and human
albumin was purchased at the Centre Regional de Transfusion Sanguine de Lille, France.
Results
Capture of serum HC-VP by ApoH
Two different approaches were used to evidence the binding between ApoH and HCV-related
particles: an RT-PCR assay, in order to detect viral RNA after the virus capture with ApoH-
coated beads and an immuno-enzymatic assay in order to detect ApoH-captured HCV anti-
gens, using ApoH-coated plates.
In the experiment shown in Fig 1A, sera from both five HCV-infected patients exhibiting
chronic hepatitis and three healthy blood donors were diluted 20-fold in an acetate buffer, and
subsequently added to ApoH-coated nanomagnetic beads. The captured HCV were detected
by RT-PCR. HCV/RNA was detected in all five patients, whereas no PCR amplicon band was
detected for the healthy blood donors’ sera.
In the experiment shown in Fig 1B, aliquots from the same sera used in Fig 1A were diluted
in Tris-buffer and then added to ApoH-coated microtitration plates. Then captured HCV
envelope antigens were detected with the anti-HCV/E2 MAb. Thus, ApoH captured E2-related
antigens from each one of the HCV-positive patients’ sera. The mean of P/N ratios for the
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Fig 1. Binding between ApoH and Hepatitis C virus-related particles. Sera from both five HCV-positive patients (HCV-pos) and three HCV-negative
healthy controls (HC) were assayed for viral detection. (A) RT-PCR detection of HCV from 20-fold diluted sera, after the viral capture by ApoH-coated beads.
Lanes M, C+ and C- respectively correspond to the DNAmolecular mass marker (1 Kb Plus DNA Ladder), the positive control (pGEM-T easy with an HCV/
PCR-insert) and the negative extraction control. (B) ApoH-ELISA immunoassay to detect HCV-related particles binding from serially-diluted sera. Aliquots
from the same sera as used for RT-PCRwere 10, 50, 500, and 5,000-fold diluted and subsequently detected with the anti-HCV/E2 MAb.
doi:10.1371/journal.pone.0140900.g001
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three healthy donors was 0.79 ± 0.07. All five HCV-positive sera exhibited significant P/N val-
ues (p<0.0001) at the 10-fold and 50-fold dilutions by an immuno-enzymatic assay. Therefore,
we used these optimal dilutions for our ApoH-binding studies by the ApoH immunoassay.
Anti-HCV/core and anti-HCV/E2 MAbs (data not shown) were assayed to detect the ApoH–
HCV interaction. Only the anti-HCV/E2 MAb gave a significant signal after the serum incuba-
tion with the ApoH-coated ELISA plate. No signal was observed with the anti-HCV/core MAb,
suggesting that the presence of whole enveloped virus is necessary to obtain a binding of HCV
with ApoH. These results indicate that ApoH was able to capture HCV particles from patient’s
sera. The simultaneous recognition by an anti-HCV/E2 MAb and the presence of viral RNA
suggests that ApoH is able to capture whole HCV particles.
To assess the involvement and specificity of coated ApoH to capture HCV from patients’
sera, plates and nanomagnetic beads were coated with another serum acute phase protein, the
α1-acid glycoprotein, the binding was measured by both immunoassay (with an anti-HCV/E2
MAb) and HCV RT-PCR. Both Fig 2A and 2B showed that the α1-acid glycoprotein was not
able to capture HCV as compared with ApoH-coated supports.
In order to assess the specificity of interaction between ApoH and HCV, we used ApoH-
coated plates to capture HCV and we assessed the inhibition of viral capture using an anti-
ApoHMAb (Fig 2C). An irrelevant non-specific antibody directed against the thyroglobulin
protein was used as control. Indeed, only the mouse anti-ApoH, 8C3, MAb strongly and specif-
ically inhibited the interaction between the ApoH-coated well plate and the HCV envelope. In
contrast, the irrelevant mouse anti-tyroglobulin, TG2, MAb used control, didn’t show any
effect on the binding between ApoH and HCV particles. These observations clearly indicate
that HCV capture was done in an ApoH-dependent manner.
To ascertain the specificity of these results as well as the efficiency of the HCV-capture by
ApoH, a broad range of sera coming from either HCV-seropositive or HCV-seronegative
patients, exhibiting different pathologies, was assayed for the detection of HCV by the ApoH
immunoassay. Table 1 shows that only sera exhibiting a COBAS HCV-RT-PCR positive result
were also HCV-positive with the ApoH ELISA immunoassay.
Influence of HCV genotype on virus binding with ApoH
Sera of 43 hospital-archived clinical samples from HCV seropositive patients, harboring the
HCV genotypes 1 to 5, as well as 10 sera from healthy blood donors were diluted in a Tris buffer
and then added to ApoH-coated microtitration plates. Once captured, the HCV envelope antigen
was detected using an anti-HCV/E2MAb. As shown in Table 2, no significant differences
between HCV genotype and ApoH-binding to HCV-related particles have been found. All the 10
sera from healthy blood donors were confirmed to be HCV-negative and the mean of P/N ratio
was 0.49 ± 0.08. Two HCV patients were not detected by the ApoH ELISA immunoassay. One of
these negative samples counted among the 11 that were previously diagnosed as HCV genotype
1; the second negative sample counted among the three that were diagnosed as HCV genotype 5.
The absence of HCV detection signal was probably due to the lower sensitivity of the ApoH
immuno-enzymatic assay as compared with the higher sensitivity of the RT-PCR format. The P/
N ratios of HCV-genotype 1 to 5 from patients’ sera exhibited significant values and were respec-
tively of 1.78 ± 0.57, 1.90 ± 0.45, 2.69 ± 1.29, 1.80 ± 0.35 and 1.7 ± 0.25.
Ultracentrifugation and density distribution of ApoH-captured HCV
particles
HCV-positive sera submitted to buoyant and sedimentation processes exhibited a high viral
heterogeneity in their gradient location. This heterogeneity may be due to the existence of
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defective particles or the association of viral particles to different serum components, including
antibodies, low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) and high-den-
sity lipoprotein (HDL).
In order to assess whether the binding of ApoH to HCV was able to retain whole HCV/
RNA particles, a pool of HCV/RNA-positive sera from untreated patients or HCV-negative
blood donors sera were spun by ultra-centrifugation at 436,000 x g. The resulting pellets, super-
natants and floating lipids were tested for their capacity to bind to ApoH-coated microtitration
plates and subsequently tested for their RNA content by RT-PCR. Table 3 shows that the
HCV-related antigens are found in both the VLDL as well as in the supernatant fractions of the
centrifuged sera. These results confirm the significant heterogeneity of distribution for hepatitis
C related particles. Table 3 also shows a significant lower signal for the pellet fraction. Compar-
atively, after centrifugation of a pool of HBV-DNA positive sera, the fraction density distribu-
tion of ApoH-captured HBV/HBsAg was different from the ApoH-captured HCV/E2. Almost
the totality of the ApoH-captured HBV/HBsAg was found in the pellet. In addition, we have
not detected either HCV/E2 or HBV/HBsAg from healthy blood donor samples after ultracen-
trifugation (data not shown).
Because all the reported studies on the HCV density have been done on the floating lipids,
we decided to characterize pelleted HCV particles. Thus, after 1 h of ultracentrifugation, the
pellet was further purified on CsCl gradient [10–60% (w/w)]. Ten-fold diluted fractions of this
gradient were tested with the ApoH-HCV ELISA immunoassay. Fig 3A shows that the higher
HCV/E2 antigen-capture by ApoH-coated plates were identified in fractions 14 to 16, respec-
tively corresponding to the CsCl densities of 1.311 and 1.450 g/mL suggesting that the HCV/E2
antigen recognized by ApoH belongs to a large macromolecular complex. In order to assess
whether the HCV-related particles captured by the ApoH-coated ELISA plates contained viral
Fig 2. Binding specificity of ApoH and HCV. (A) One hundred microliters of sera from five HCV-positive
patients were incubated with either the α1-acid glycoprotein- or the ApoH- coated plates. The HCV-related
antigens were revealed with the anti-HCV/E2 MAb. The bars represent the corresponding means with SD. (B)
Sera from both a single healthy control (HC) and one HCV-pos were either incubated with α1-acid
glycoprotein or with the ApoH-coated magnetic beads and HCV/RNA was subsequently detected by
RT-PCR. M, C+ and C- respectively correspond to the DNAmolecular mass marker (1 Kb Plus DNA Ladder),
the positive control (plasmid pGEM-T easy with an HCV/PCR-insert) and the negative PCR control. (C) The
inhibition of the interaction between ApoH and HCV, previously shown, was assessed either by using the
anti-ApoH, 8C3, MAb, or the anti-thyroglobulin, TG2, irrelevant MAb. Increasing concentrations of either 8C3
(solid line) or TG2 (hatched line) were used for the pre-incubation of the ApoH-coated plate with a 50-fold
diluted HCV-positive serum.
doi:10.1371/journal.pone.0140900.g002
Table 1. Detection of HCV antigen with the HCV-ApoH immunoassay on patients’ sera exhibiting different infections.
Serum samples Negative ApoH-immunoassay Positive ApoH-immunoassay Positive COBAS HCV-RT-PCR
Healthy controls, blood donors (n = 100) 100 0 0
Autoimmune diseases (n = 20) 20 0 0
Multiple Sclerosis (n = 15) 15 0 0
HIV/AIDS (n = 10) 9 1a 1
HAV (n = 10) 10 0 0
HBV (n = 20) 15 5 b 5
HCV–seropositive (n = 120) 6 c 114 114
aHCV- HIV co-infected patients
bHCV- HBV co-infected patients
c These samples also exhibited a negative RT-PCR COBAS1 TaqMan1 HCV Test, v2.0- result.
doi:10.1371/journal.pone.0140900.t001
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RNA, an open home-made HCV-RT-PCR was performed for some gradient fractions chosen
along the shape of the CsCl gradient curve. HCV/RNA was detected in fractions 14 and 15 (Fig
3B). Thus, the viral RNA detection was well correlated with the HCV/E2 immunoassay detec-
tion (Fig 3A). To determine the structural features of viral related particles captured by ApoH,
electron microscopy analyses were performed with purified particles from the 1.45 g/mL frac-
tion of the CsCl centrifugation gradient. In this fraction, virus-like spherical particles, 55–65
nm in diameter were observed (Fig 3C).
Thereafter, we also tried to identify lipoproteic fractions, from HCV/RNA-positive but
untreated patients, exhibiting an affinity for ApoH. Thus, a pool (n = 10) of plasma previously
used for density analysis was fractionated into four parts, corresponding to the floating densi-
ties of VLDL (<1.006 g/L), LDL (1.006 to 1.063 g/L), HDL (1.063< d< 1.210 g/L) as well as
to the bulk plasma proteins. Fig 4 shows the presence of HCV-RNA in VLDL and HDL lipo-
proteic fractions. In the LDL fraction, HCV-RNA was not detected in the presence of ApoH-
beads. Plasma fractions from healthy blood donors remained negative for this test (data not
shown). The fact that both HCV RT-PCR and HCV ApoH ELISA tests were positive, confirms
that ApoH likely binds to nucleic acid full HCV particles.
Metal ions influence the ApoH binding to HCV
In a previous work [44], we have reported that metal ions influence the HBsAg recognition by
ApoH. In order to verify if these metal ions affect the ApoH-HCV binding, we tested the viral
capture with ApoH-coated nanomagnetic beads in the presence of different ions, including
Fe2+, Fe3+, Ca2+, Mg2+, Mn2+, Zn2+ or Cu2+. Fig 5 shows that similar signals were obtained
after the addition of Ca2+, Mg2+, Mn2+ or Zn2+ into the capture medium. However, the pres-
ence of Fe2+, Fe3+ or Cu2+ induced respectively significant three-, two- and five-fold increases
of the captured HCV copy numbers.
Table 2. ApoH-immunoassay on different sera from patients harbouring different HCV genotypes.
HCV-positive patients HCV-1 a HCV-2 a HCV-3 a HCV-4 a HCV-5 a TOTAL of positive samples
HCV/RNA detection using COBAS HCV RT-PCR (without ApoH) 11 9 10 10 3 43
HCV/E2 detection using the ApoH-immunoassay 10b 9 10 10 2c 41
HCV detection in healthy controls 0 0 0 0 0 0
a, corresponding HCV genotype
b, c This test didn’t detect one COBAS RT-PCR HCV-positive sample.
doi:10.1371/journal.pone.0140900.t002
Table 3. Detection of HCV and HBVwithin different centrifuged serum fractions using the appropriate
ApoH-immunoassay.
Viral detection in different seruma fractions HCV/E2 detection (P/N) HBV/HBsAg detection (P/N)
Serum before centrifugation 11.20 ± 6.43 34.30 ± 6.67
Floating lipids (VLDL) 12.54 ± 7.01 2.00 ± 1.19
Serum after centrifugation 10.62 ± 5.37 9.70 ± 5.41
Pellet 6.66 ± 1.44 50.80 ± 3.34
a Sera from patients with chronic hepatitis C or B were ultracentrifuged for 1 h at 436,000 x g and
subsequently tested for HCV or HBV using the corresponding virus-ApoH immunoassay. The presence of
viral antigens was revealed using either anti-E2 or anti-HBsAg MAbs. Results are expressed as P/N
values.
doi:10.1371/journal.pone.0140900.t003
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Fig 3. ApoH binds the RNA-containing HCV-related particles. (A) Isolation of HCV-related particles by
ultracentrifugation. After the ultracentrifugation at 436,000 x g for 4 h at 4°C of pooled sera from HCV/RNA-
positive patients, 100 μL fractions of the pellet were layered onto a 900 μL CsCl gradient ranging from 10% to
60% (w/w) (open dots) and ultracentrifuged again at 300,000 g for 18 h at 4°C. The resulting gradient
fractions were ten-fold diluted and tested using the HCV-ApoH immunoassay (black dots). (B) The presence
or the absence of HCV-RNA in the centrifugation pellet was revealed by RT-PCR, prior to the CsCl gradient
Interactions between HCV and the ApoH Acute Phase Protein
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Iron and copper are redox-active metals and involved in oxidative injury mechanisms,
including the lipid peroxidation. To assess whether anionic lipid peroxidation mechanisms are
involved in the HCV recognition by ApoH, polymyxin B was added at a concentration of
100 μg/mL. Fig 5 also shows that the addition of polymyxin B does not affects the ApoH bind-
ing of HCV, suggesting that this binding does not depend on anionic phospholipids.
Correlation between the results from post-ApoH-HCV capture home-
made qRT-PCR and direct COBAS qRT-PCR assay
Forty-eight hospital-archived HCV-seropositive samples, with a viral load above 103 IU/mL
were processed in parallel using (i) the Real-Time COBAS1 TaqMan1HCV Test, v2.0 with-
out the ApoH-sample pretreatment step and (ii) a home-made HCV RT-PCR assay done after
the ApoH-sample pretreatment step. A significant correlation was found for both methods
(Fig 6A) (r2 = 0.8261, P< 0.0001, Pearson’s r = 0.9089, 95% CI = 0.8423–0.9482 for n = 48) for
a viral load concentration varying between 103 and 107 IU/mL. The Bland–Altman plot shows
the differences between the two assays (Fig 6B). The bias (0.086) to these measures is very close
to zero, indicating that the obtained results using both methods generate similar results on
plasma with high viral loads, thus confirming their correlation.
Forty seven hospital-archived samples from HCV-seropositive patients, including 22 of
them exhibiting a viral load below 103 IU/mL and 25 of them, exhibiting a negative COBAS
HCV RT-PCR, were processed to detect or not HCV/RNA after an ApoH-sample pretreatment
using ApoH-coated magnetic beads. All the 22 serum samples from HCV-seropositive patients,
with previously detected low viral loads, were also found positive with the two-step ApoH-cap-
ture and RT-PCR method and some of them exhibited a higher HCV-load. Eleven samples out
of 25 previously determined COBAS HCV-RT-PCR negative sera turned RT-PCR HCV-posi-
tive after the ApoH-sample pretreatment step. The absence of HCV/RNA detection was con-
firmed for the remaining 14 samples out of these 25 samples. Obviously, for these samples we
didn’t statistically find any correlation between the two methods.
and after the gradient, in some of the resulting gradient fractions (CsCl-fr 5, 7, 9, 13, 14, 15 and 18). (C) CsCl
ultracentrifugation gradient fractions corresponding to a density of 1.45 g/mL were layered directly onto
ApoH-coated electron microscopy grids to observe the purified HCV-particles as previously done for HBV
[44].
doi:10.1371/journal.pone.0140900.g003
Fig 4. ApoH captures HCV/RNA-containing particles, from low-density and high-density plasma fractions. A pool of 10 HCV/RNA-positive untreated
patients was separated into three fractions, respectively corresponding to the floating densities of VLDL, LDL and HDL. One hundred μL of VLDL, 10 μL of
LDL and 1 μL of HDL were respectively incubated with 10 μL of ApoH-coated nanomagnetic beads and HCV/RNA was submitted to a home-made HCV
RT-PCR. Lanes M, C+ and C- respectively correspond to the DNAmolecular mass marker (1 Kb Plus DNA Ladder), the positive control (plasmid pGEM-T
easy with an HCV/PCR-insert) and negative PCR control.
doi:10.1371/journal.pone.0140900.g004
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Enhanced detection of HCV through pre-analytical sample treatment
with ApoH-coated nanomagnetic beads
To explain both results above, results on viral loads below 103 IU/mL and those of Fig 4 show-
ing that, for 100 μL of VLDL, an HCV-RNA signal was observed only in the presence of
ApoH-coated nanomagnetic beads (lane #1 as compared with lane #2), we hypothesized that
the HCV capture by ApoH-coated nanomagnetic beads permitted its sensitive detection by a
prior viral cleansing and the elimination of PCR inhibitors. Indeed, we previously reported for
the cardiopulmonary ANDES hantavirus [56] that, despite a relatively high viral load>5x104
per reaction, viruses were detected only in the presence of a prior ApoH-sample pretreatment.
Thus, in this case the sample pretreatment cleansed inhibitors rather than concentrated viruses.
This was checked using serially diluted HCV-RNA-positive serum submitted to our home-
made HCV RT-PCR in the presence or the absence of ApoH-coated nanomagnetic beads. For
this tested single serum, a strong difference of sensitivity was observed between the results
obtained in the presence of ApoH-beads and in their absence (Fig 7A). Indeed, in the presence
of ApoH-coated beads, the tested serum was yet HCV positive at the 104–fold dilution, while
for the same dilution, in the absence of beads, no signal was detected. As noted above, 25-tested
Fig 5. Effect of metal ions or polymyxin B on the HCV-capture by the ApoH system. Sera from two
HCV-infected patients were preincubated (or not) for 30 min at 37°C with polymyxin B (P.B., 100 μg/mL) to be
subsequently pretreated with different metal ions (2 mmol/L) and with ApoH-coated beads in the conditions
stated in the material and method section. Then the ApoH-HCV capture was revealed by an open home-
made HCV-RT-qPCR. This experiment represents four similar experiments.
doi:10.1371/journal.pone.0140900.g005
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Fig 6. Statistical comparisons and correlations between positive qRT-PCRHCV detection with and
without the preparative ApoH-capture HCV step. (A) Scatter-plot comparing the HCV loads using the real-
time RT-PCR COBAS1 TaqMan1HCV Test, v2.0 alone versus the open home-made HCV real-time
RT-PCR assay after the ApoH-HCV capture. Forty-eight clinical samples from HCV-infected patients were
tested. The solid line represents the regression curve. (B) Bland-Altman plot depicts the correlation of the
viral load figures from COBAS HCV real-time RT-PCR assay alone and the figures resulting from the HCV
real-time RT-PCR assay associated with the ApoH sample pretreatment (n = 48). The graph displays a
scatter diagram of the differences plotted against the averages of the two measurements. Horizontal lines are
drawn at the mean difference and at the mean difference ± 1.96 times the standard deviation, SD, of the
differences (95% limits of confidence).
doi:10.1371/journal.pone.0140900.g006
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HCV-seropositive samples were COBAS HCV-PCR negative. Eleven COBAS HCV-PCR nega-
tive sera generated a positive result with the home-made HCV RT-PCR following sample pre-
Fig 7. Enhanced detection of HCV following HCV capture with ApoH-coated beads. (A) In the presence or in the absence of the ApoH-coated beads,
HCV/RNA from 10-fold serial dilutions of a single HCV-infected patient serum was detected in gel after HCV RT-PCR amplification. HCV-negative healthy
control serum (HC). (B) List of HCV sequences from 11 HCV-seropositive patients (samples #: 32, 36, 148, 169, 171, 151, 459, 450, 465, 448, 445) with prior
negative COBASHCV RT-PCR, but tested as HCV-positive with the two-step detection method consecutively including the ApoH-sample pretreatment and
the home-made HCV RT-PCR.
doi:10.1371/journal.pone.0140900.g007
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treatment with ApoH-beads. The presence of HCV was confirmed by sequence analysis. Thus,
when these sequences (Fig 7B) were compared with several annotated sequences from different
nucleic acid sequence banks using the NCBI-Blast sequence comparison software1, it
appeared that they exhibited different sequences close to different HCV genotypes (Table 4).
Thus, introducing the two-step procedure, we confirmed that ApoH-sample preparation cou-
pled with the home-made HCV RT-PCR was able to detect HCV in 44% of samples, from the
archived-hospital collection, that were previously HCV-negative with COBAS HCV RT-PCR.
Discussion
In this study, we have evidenced that the scavenger acute phase protein ApoH was able to cap-
ture RNA-containing HCV particles from infected patients’ sera independently of the tested
genotypes. This binding was specific as an anti-ApoHMAb was able to almost totally abrogate
this interaction, whereas no effect was observed in the presence of α1 acid-glycoprotein,
another acute phase plasma protein. When comparing HBV and HCV-positive sera, after
ultra-centrifugation at 436,000 x g (Table 2), the presence of ApoH bound to the HCV glyco-
protein E2 was dispersed in almost all the ultracentrifuged fractions including in the floating
lipid phase, supernatant and pellet, whereas the vast majority of captured HBsAg of HBV was
found in the pellet fraction. Thus, HCV exhibited highly heterogeneous density as compared
with HBV.
To characterize the nature of HCV particles involved in its binding with ApoH, we per-
formed different analyses, including a CsCl centrifugation gradient, detection of different gra-
dient fractions with the anti-HCV/E2, 3A2C11, MAb, HCV RT-PCR, as well as transmission
electron microscopy. HCV particles found in vivo are reported exhibiting heterogeneous densi-
ties, ranging from 1.06 to 1.25 g/mL [23, 37–40]. These differences were attributed to the pres-
ence or the absence of host’s lipoproteins, antibodies bound to the circulating viral particles or
circulating RNA-positive HCV nucleocapsids [57, 58] that could mask or interfere with the
ApoH binding activity. In order to make a preparative viral purification, we have done an
Table 4. Nucleic acid sequence identification of HCV amplicons yielded with the two-step HCV detec-
tion procedure including ApoH-virus capture and home-made HCV RT-PCR.
Sample Blast (Annotated accession numbers)a Identity e-
value
32 gb|AF217306.1|AF217306 Hepatitis C virus clone Sot24 5'UTR sequence 96% 9e-92
36 gb|L34369.1|HPCBCC Hepatitis C virus 5' non-coding region 97% 1e-94
148 emb|LN681401.1| Hepatitis C virus 5'UTR region, genotype 1b 99% 9e-102
151 gb|DQ516083.1| Hepatitis C virus subtype 4d isolate 24 polyprotein gene 98% 4e-85
169 gb|GQ418227.1| Hepatitis C virus genotype 1 isolate 06.10.001 5' UTR 98% 2e-93
171 gb|HM771266.1| Hepatitis C virus isolate AA0828 5' UTR 95% 3e-96
445 dbj|AB523078.1| Hepatitis C virus subtype 1a gene for core protein 99% 6e-67
448 emb|LN681369.1| Hepatitis C virus 5'UTR region, genotype 4a, isolate 3cf 99% 9e-61
450 gb|GQ418214.1| Hepatitis C virus genotype 1 isolate 07.10.030 5' UTR 100% 3e-85
459 gb|KP888622.1| Hepatitis C virus isolate US069 5' UTR 98% 8e-82
465 gb|EU256007.1| Hepatitis C virus subtype 1a isolate HCV-1a/US/BID-V464/
2006
91% 3e-60
a HCV sequences present in serum samples from HCV seropositive patients with negative RT-PCR
COBAS1 TaqMan1 HCV Test, v2.0, but tested positive with the two-step ApoH-HCV capture and HCV
detection method.
doi:10.1371/journal.pone.0140900.t004
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ultracentrifugation round of a pool of infected patients’ sera. After ultracentrifugation, the
HCV/E2 glycoprotein was mainly detected in the floating lipids phase as well as in the superna-
tant and in a lesser extent, in the pellet. Since the lipid-floating phase mainly contains VLDL
and that the HCV-VLDL complexes have already been studied, we decided to assess the pres-
ence of HCV particles in the pellet.
For the studied sera, the maximal HCV/E2 antigen-captures by ApoH-coated plates were
found at the respective densities of 1.311 and 1.450 g/mL. Density amplitudes vary from 1.239
to 1.450 g/mL in function of patient’s sera (data not shown) suggesting that the antigen recog-
nized by ApoH belongs to a large macromolecular complex. High-density molecular complexes
containing HCV/RNA have been reported but not always characterized [59]. Some of these
high-density HCV have been reported as lipoprotein-free virus [19]. Both RT-PCR and elec-
tron microscopy observations on ApoH-coated grids evidenced that these complexes contain
HCV/RNA and are mainly composed of spherical particles of 55–65 nm in diameter, thus
establishing the binding of HCV particles to ApoH.
The HCV-ApoH capture applied to sequentially ultra-centrifuged plasmas confirmed the
presence of HCV as a lipoviral particle, in both VLDL and HDL fractions, but not in the LDL
one, thus confirming the association of HCV with different lipoprotein fractions that have
been already described [60]. The Polymyxin B nonapeptide, an antibiotic showing a high affin-
ity for anionic phospholipids [61], didn’t interfere with the ApoH-HCV interaction, suggesting
that this binding is done in an anionic phospholipid-independent manner, which then differs
from the interaction observed between HBV and ApoH [44]. This is in line with the VLDL and
HDL composition [62] that do not harbour the anionic phospholipids, such as phosphatidyl
serine or cardiolipin, which exhibit an affinity for ApoH.
ApoH binding to phospholipids is reported to depend on their oxidation state [63]. Oxi-
dized forms of LDL-associated ApoH are frequently detected in sera from patients with APS
and/or systemic lupus erythematous [64]. Oxidized forms of LDL are also significantly
increased in patients with chronic hepatitis C and correlated with the corresponding viral load
[51]. HCV causes oxidative stress by a variety of processes [52], including metal unbalance
[53]. Oxidant and non-oxidant metal ions, such as iron, copper and zinc differently affect the
hepatitis disease. HCV-infected patients display low plasma concentrations of zinc but high
concentrations of copper and iron as compared with control subjects [65]. The oxidative
potential of copper on LDL has been already reported, and in addition, plasma copper levels
correlates with viral load [66, 67]. Iron is essential for cell survival, and its excess or deficiency
may lead to disease. Increased amounts of iron appear to facilitate infections and this overload
linked to the physiopathology of viral hepatitis has been reported [68, 69]. Iron overload is
associated with both the increased DNA damage and the lipid peroxidation in HCV-infected
patients [70]. In contrast, zinc has antioxidant properties, and its level in chronic liver disease
due to hepatitis C is inversely correlated with viral load [66]. This metal has been described as
having inhibitory effect on spontaneous lipid peroxidation [71]. Our results on the effect of
metal ions on the ApoH–HCV binding confirmed that oxidative mechanisms are involved in
these interactions. Thus, ApoH–HCV binding was increased by the addition of iron and cop-
per, which are also involved in both oxidative injury and lipid peroxidation, whereas zinc
seems to have no influence. The interaction between ApoH and HCV does not necessarily
involve interactions between ApoH and HCV proteins. Indeed, the presence of ApoH has been
described in all major lipoprotein density fractions [72]. Moreover, ApoH binds oxidized phos-
pholipids [63] and specifically binds to oxidized LDLs [73]. Thus, ApoH could bind to HCV
particles via the phospholipids in function of their configuration and their oxidative status.
Altogether, these data lead us to hypothesize that ApoH could play a pivotal role in the evo-
lution of HCV infection, either favouring or inhibiting the infection. In favour of the
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facilitating hypothesis it has been reported that lipoprotein receptors such as SR-BI or LDL-R
[74] are reported to be involved in the uptake of the HCV-associated lipoproteins into hepato-
cytes. All lipoprotein receptors are able to bind ApoH [75] and the complex resulting from
these interactions could participate in either endocytosis or signal transduction [76]. Thus,
ApoH in association with HCV particles, as described for the interaction between HCV and
ApoE [66] could facilitate the viral entry via several lipoprotein receptors. In favour of the inhi-
bition hypothesis, it has been reported that ApoH is able to activate the lipoprotein lipase [77],
which inhibits HCV infection by blocking the virus cell entry [78]. Furthermore, ApoH was
found to be associated with a rapid clearance of liposomes in vivo [79] suggesting a significant
role in the immune clearance of the “non-self” particles, such as HCV. The clearance phenome-
non could depend on the presence of free active form of the plasmatic ApoH in the organism
resulting in different possible pathological consequences of the infection. To support this
hypothesis, new data using liver slices and HCV particles report that ApoH limits the HCV
replication, furthermore a correlation was observed between high plasma ApoH-concentra-
tions and improved clinical outcome of HCV-infected patients [80].
Here, we have shown that the ApoH-coated beads can be used as an HCV-capture method
to enhance the sensitivity of virus detection, resulting either from an endpoint or a quantitative
RT-PCR as shown in Fig 6A and 6B. It is of note that in some samples split in two equal vol-
umes, the initial amount of viruses was higher in the presence of ApoH (these initial viral
amounts were not saturating for the ApoH-magnetic beads) as compared with the experiment
done in the absence of ApoH. Therefore, most of the time this method is able to reveal the pres-
ence of HCV in HCV-seropositive clinical samples with negative COBAS HCV RT-PCR detec-
tion. We have processed 95 HCV-seropositive hospital-archived patients’ samples, by using the
Real-Time COBAS HCV PCR in the absence of the ApoH-sample pretreatment as well as by
using a home-made HCV real-time RT-PCR done after the ApoH-sample pretreatment. For
viral loads above 103 IU/mL, a significant correlation was found between both methods. In
contrast, for viral loads below 103 IU/mL or negative COBAS HCV RT-PCR samples from hos-
pital-diagnosed patients, it appeared that the ApoH-sample pretreatment significantly
improved the sensitivity of HCV detection in a genotype-independent manner. In particular,
this ApoH sample pretreatment permits to easily detect HCV in those cases where the sole
application of current methods generates erroneous false-negative HCV diagnoses. Thus 11
out of 25 (44%) seropositive samples that were COBAS HCV-PCR-negative were found HCV-
positive with the open home-made HCV-PCR following the sample preparation with the
ApoH-viral capture method. The presence of HCV/RNA was confirmed by DNA sequencing.
The Blast nucleic acid sequences similarities with different annotated data banks showed that
these sequences belonged to different HCV genotypes. In order to explain these differences
between the presence of HCV in the presence or in the absence of ApoH beads, we have
hypothesized that ApoH-coated nanomagnetic beads permitted HCV sensitive detection by a
prior viral cleansing and elimination of PCR inhibitors. Different studies have reported the
presence of PCR inhibitors in nucleic acids extracts, while others underline the adequacy of
sampling and nucleic acids extraction in yields of microbial nucleic acids [81, 82]. Conse-
quently, the sample pretreatment with ApoH could be useful tool to permit a sensitive detec-
tion of HCV in samples from patients with very low viral loads as well as for a more accurate
manner to monitor the efficiency and management of anti-HCV therapies.
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